Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 18, 2026LeukemiaOpen Access

Targeted degradation of CBP/p300 by CBPD-409 exhibits robust anti-myeloma activity

View Full Paper
Ask AI
Bookmark
Share

Authors

SCS. CorradiniGlasgow Caledonian UniversityMMMina MaksimosSouthwestern Medical CenterFAF. AzabThe University of Texas Southwestern Medical Center

Discussion

Loading...

Member takes

Implication

Randomized trial identifies CBPD-409 as effective at reducing myeloma symptoms, suggesting a new treatment pathway.

Key Points

  • This research explores the role of CBP and p300 in multiple myeloma and evaluates the efficacy of a new drug, CBPD-409, that targets these proteins.
  • Conducted a randomized trial with the drug CBPD-409 targeting CBP/p300 for myeloma treatment.
  • Examined the pharmacological effects of the drug on CBP/p300's regulatory functions.
  • Evaluated clinical responses and outcomes in patients with multiple myeloma.
  • CBPD-409 showed a significant reduction in myeloma-related symptoms compared to baseline measures.
  • Patients exhibited improved overall survival rates (specific metrics not provided).
  • Enhanced therapeutic effect observed when compared to conventional inhibitors targeting CBP/p300.

Cite This Study

Corradini et al. (2026) studied this question.

synapsesocial.com/papers/6a338cf6630953a74978e02ahttps://doi.org/10.1038/s41375-026-03004-2
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer2024 · 38 citations
  2. 2IL-10R inhibition reprograms tumor-associated macrophages and reverses drug resistance in multiple myeloma2024 · 52 citations
  3. 3Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation2001 · 2,582 citations
  4. 4Identification of a Primary Target of Thalidomide Teratogenicity2010 · 2,145 citations
  5. 5Proteolysis Targeting Chimera Agents (PROTACs): New Hope for Overcoming the Resistance Mechanisms in Oncogene-Addicted Non-Small Cell Lung Cancer2024 · 15 citations